Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictive factors associated with pemetrexed acute toxicity.
Bonnet M, Jouinot A, Boudou-Rouquette P, Seif V, Villeminey C, Arrondeau J, Vidal M, Batista R, Wislez M, Blanchet B, Goldwasser F, Thomas-Schoemann A. Bonnet M, et al. Among authors: villeminey c. Eur J Clin Pharmacol. 2023 May;79(5):635-641. doi: 10.1007/s00228-023-03478-4. Epub 2023 Mar 23. Eur J Clin Pharmacol. 2023. PMID: 36951965
Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study.
Boudou-Rouquette P, Arrondeau J, Gervais C, Durand JP, Fabre E, De Percin S, Villeminey CV, Piketty AC, Rassy N, Ulmann G, Damotte D, Mansuet-Lupo A, Giraud F, Alifano M, Wislez M, Alexandre J, Jouinot A, Goldwasser F. Boudou-Rouquette P, et al. Among authors: villeminey cv. EBioMedicine. 2021 Nov;73:103630. doi: 10.1016/j.ebiom.2021.103630. Epub 2021 Oct 20. EBioMedicine. 2021. PMID: 34688030 Free PMC article.
Prevalence of drug-drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management.
Bellesoeur A, Gataa I, Jouinot A, Mershati SE, Piketty AC, Tlemsani C, Balakirouchenane D, Monribot A, Vidal M, Batista R, de Percin S, Villeminey C, Alexandre J, Goldwasser F, Blanchet B, Boudou-Rouquette P, Thomas-Schoemann A. Bellesoeur A, et al. Among authors: villeminey c. Cancer Chemother Pharmacol. 2021 Oct;88(4):741-751. doi: 10.1007/s00280-021-04311-4. Epub 2021 Jul 24. Cancer Chemother Pharmacol. 2021. PMID: 34304283
Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France.
Bonnet C, Boudou-Rouquette P, Azoulay-Rutman E, Huillard O, Golmard JL, Carton E, Noé G, Vidal M, Orvoen G, Chah Wakilian A, Villeminey C, Blanchet B, Alexandre J, Goldwasser F, Thomas-Schoemann A. Bonnet C, et al. Among authors: villeminey c. Cancer Chemother Pharmacol. 2017 May;79(5):1051-1055. doi: 10.1007/s00280-017-3291-z. Epub 2017 Mar 30. Cancer Chemother Pharmacol. 2017. PMID: 28361167